EARS Auris Medical Holding AG

0.36
0  -0%
Previous Close 0.36
Open 0.36
Price To Book -18
Market Cap 14265550
Shares 39,626,529
Volume 619,702
Short Ratio
Av. Daily Volume 1,826,287

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Open label safety trial data released April 24, 2017 and May 9, 2017.
Keyzilen (AM-101) - AMPACT open-label
Acute inner ear tinnitus
Phase 3 HEALOS trial did not meet primary endpoint - November 28, 2017.
AM-111 HEALOS
Acute inner ear hearing loss
Phase 3 data released March 13, 2018 - primary endpoint not met.
Keyzilen (AM-101) - TACTT3
Acute inner ear tinnitus
Phase 3 ASSENT trial terminated - November 28, 2017.
AM-111 ASSENT
Acute inner ear hearing loss
Phase 2 trial (REACH) enrollment pending funding.
AM-111 REACH
Surgery-induced hearing loss
Phase 3 trial did not meet primary endpoints
AM-101 (Keyzilen) - TACTT2
Acute inner ear tinnitus
Phase 2 trials to commence 1Q 2019.
AM-125
Vertigo
Phase 1b trial to initiated soon.
AM-201
Healthy volunteers